The quality vaccine research funded by the EUR 30 million FP7 High Impact Project on Advanced Immunization Technologies (ADITEC) is confirmed by the bibliometric analysis of the scientific papers produced by the project.
We are pleased to announce that Surrey CRC was once again awarded MHRA Phase I accreditation in December 2014.
This is the third time that the Centre has passed a Phase I inspection in the past 6 years. These inspections involve reviewing all the centre’s processes to ensure that staff do everything they can to ensure the safety of research participants and guarantee the integrity of the data produced..
The Surrey Clinical Research Centre was recently at the centre of an international effort with European Commission funding to design and test a vaccine to prevent HIV/AIDS. The vaccine employed several highly innovative concepts including nasal delivery to produce strong genital tract immunity, liposomal formulation, and an uniquely designed active component to make virus-blocking antibodies. The SCRC conducted the first in human clinical trial of this product, drawing on its extensive expertise in translational medicine, mucosal immunology, and Phase 1 trial accreditation.